Urologists Prefer Live CME Activities Over Online

At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats in which they wished to receive continuing medical education (CME). Thirty-six individuals completed the survey, of whom 35 (97.2%) were physicians and other prescribers of medication. Results showed that despite the ever-increasing ubiquity of technology in our society, uro...
Continue reading

Castration-Resistant Prostate Cancer: Guiding Patients Through Treatment With Brenda Martone, MSN, ANP-BC, AOCNP

‚ÄčAndrogen deprivation therapy is a cornerstone of treatment for progressive prostate cancer, but over time, many patients stop responding to this treatment, developing a resistance to castration. Until recently, nonmetastatic castration-resistant prostate cancer (CRPC) lacked effective treatment options; this situation has changed dramatically with the rise of several new agents. Metastatic CRPC is the primary cause of prostate-related mortality, yet advances in treatment are extending survival....
Continue reading

Learning Needs: Checkpoint Inhibitors in Cervical Cancer

Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has revealed significant baseline knowledge gaps in the area of checkpoint inhibitor therapies for advanced cervical cancer.Three hundred and ninety-seven learners took part in the educational activity and completed the pre-activity assessment, and 375 of these finished the activity a...
Continue reading

Educational Need in Castration-Resistant Prostate Cancer

Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response.Baseline data collected from i3 Health's continuing med...
Continue reading

Knowledge Gaps in the Treatment of Carcinoid Syndrome

Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symptoms of carcinoid syndrome can negatively impact patients' quality of life and functioning.Baseline data collected from a continuing nursing education (CNE)-approved Oncology Nursing Strategy Session titled Optimizing Management of Carcinoid Syndrome...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.